Hepatorenal syndrome: diagnosis, management, and terlipressin

Cinematic clinical photograph of a cirrhotic patient with ascites on a combined terlipressin and albumin infusion, ICU setting, clinical-blue lighting, no text, no identifiable people — FigureHepatorenal syndrome is a functional AKI — terlipressin plus albumin can reverse it; liver transplant cures it.

Pathophysiology of hepatorenal syndrome splanchnic vasodilation renal vasoconstriction — FigureHRS is functional AKI — splanchnic vasodilation, effective hypovolaemia, RAAS activation, intense renal vasoconstriction without structural kidney disease.

Terlipressin plus albumin protocol and transplant pathway for HRS-AKI — FigureTerlipressin + albumin (CONFIRM) can reverse HRS-AKI; monitor for respiratory failure; liver transplant is definitive therapy.

HRS Type 1 (AKI) vs Type 2 (AKD)

Feature	Type 1 (HRS-AKI)	Type 2 (HRS-AKD)
Onset	RAPID (doubling creatinine <2 weeks)	SLOW (weeks-months)
Creatinine	>2.5 mg/dL (220 μmol/L)	1.5-2.5 mg/dL (133-220 μmol/L)
Clinical	Acute deterioration, often precipitant	Stable, refractory ascites
Mortality (untreated)	80% at 2 WEEKS	70% at 6 MONTHS
Treatment	Terlipressin + albumin → urgent transplant	TIPS, albumin, transplant (elective)
Natural history	Days-weeks (death from multi-organ failure)	Months (death from renal failure/ascites)

[1]

HRS-AKI vs prerenal AKI vs ATN — diagnostic differentiation

Feature	Prerenal AKI	HRS-AKI	ATN (intrinsic)
Mechanism	True volume depletion	Functional vasomotor (splanchnic vasodilation)	Tubular injury (ischaemic/toxic)
Urine Na	<20 mEq/L	<10 mEq/L (very low)	>30 mEq/L
FENa	<1%	<1%	>2%
Urine sediment	Bland	Bland (no casts)	Muddy-brown granular casts
Urine osm	>500	>500	Isotonic (~300)
Response to albumin	YES (creatinine falls)	NO (the defining test)	NO
Renal US	Normal	Normal	Normal (or in chronic CKD)
Proteinuria	None	<500 mg/day	Variable
Treatment	Volume (saline/albumin)	Terlipressin + albumin	Treat cause, RRT
Histology	Normal	NORMAL (functional)	Tubular necrosis

[1]

Terlipressin vs noradrenaline vs octreotide/midodrine — vasoconstrictor comparison

Feature	Terlipressin	Noradrenaline	Octreotide + Midodrine
Mechanism	V1 vasopressin agonist (splanchnic)	alpha-1 agonist (systemic + splanchnic)	Octreotide = somatostatin analogue; midodrine = alpha-1 agonist
FDA-approved for HRS	YES (2022, first agent)	No (off-label)	No (off-label, weak)
Route	IV bolus Q4-6h or continuous infusion	Continuous IV infusion (central line)	SC octreotide + PO midodrine
Dose	1-2 mg Q4-6h or 2-12 mg/day infusion	0.5-3 mg/h titrate to MAP	Octreotide 100-200 mcg SC TDS + midodrine 2.5-7.5 mg PO TDS
Efficacy (HRS reversal)	32-50% (CONFIRM, REVERSE)	40-50% (non-inferior to terlipressin)	LOWEST — ~15-25%
Setting	Ward or ICU; ICU for continuous infusion	ICU only (central line, titration)	Ward (oral/SC), last-resort
Main adverse effect	Ischaemia (MI, mesenteric, digital), respiratory failure (fluid overload)	Peripheral/renal ischaemia, arrhythmia	Bradycardia, hypertension, diarrhoea
Cost/availability	Expensive; not universally available	Cheap; every ICU	Cheap; widely available
Evidence	CONFIRM (n=300), REVERSE (n=178)	Alessandria 2007 pilot (n=22); multiple meta-analyses show non-inferiority	Cavallin 2015 RCT — INFERIOR to terlipressin

[1]

Diagnosis and management of hepatorenal syndrome

SUSPECT HRS — cirrhotic patient with ascites develops AKI (creatinine rise ≥26.5 μmol/L in 48h or ≥1.5x baseline). VERY COMMON in decompensated cirrhosis
EXCLUDE other causes of AKI — (a) Volume depletion (diuretics, diarrhoea, GI bleed) — give ALBUMIN 1 g/kg/day × 2 days. If creatinine improves → prerenal (NOT HRS). (b) ATN (sepsis, hypotension, nephrotoxins) — check urine sediment (granular casts → ATN), urine Na (>30 → ATN), FENa (>2% → ATN). (c) Glomerulonephritis (proteinuria >500, haematuria). (d) Obstruction (renal ultrasound)
ICA 2015 CRITERIA for HRS-AKI (ALL must be met): (a) Cirrhosis + ascites. (b) Creatinine >1.5 mg/dL (133 μmol/L). (c) NO improvement after albumin (1 g/kg/day × 48h). (d) NO shock. (e) NO nephrotoxic drugs. (f) NO structural kidney disease (normal urine sediment, proteinuria <500, normal renal US)
TREATMENT — TERLIPRESSIN + ALBUMIN — (a) Terlipressin: 1-2 mg IV every 4-6h (or continuous infusion 2-12 mg/day). CONFIRM trial: 32% HRS reversal vs 17% placebo. FIRST FDA-approved for HRS. (b) Albumin: 20-40 g/day (maintains intravascular volume, improves splanchnic vasoconstriction effect). (c) Duration: until creatinine <1.5 or 14 days max. (d) MONITOR: creatinine, BP, fluid status. (e) CAUTION: ischaemic side effects (MI, mesenteric, digital — 4%), fluid overload
ALTERNATIVES — (a) Noradrenaline infusion (alternative vasoconstrictor — 0.5-3 mg/h — if terlipressin unavailable). (b) Octreotide + midodrine (LESS effective — only if no terlipressin/noradrenaline). (c) TIPS (transjugular intrahepatic portosystemic shunt — for selected, stable patients). (d) RRT (if refractory — bridge to transplant)
LIVER TRANSPLANT — definitive — HRS is REVERSIBLE with transplant (kidney function recovers — functional, not structural). PRIORITY: MELD score (HRS raises MELD → higher priority). Post-transplant: renal recovery in 60-80% (may need temporary RRT in 20-30%)

[1]

Terlipressin dosing and titration protocol (continuous infusion preferred in ICU)

BASELINE WORKUP — confirm HRS-AKI (ICA criteria), check ECG (terlipressin can prolong QT), review contraindications (ischaemic heart disease, peripheral vascular disease, uncontrolled arrhythmia — relative cautions, weigh benefit vs risk). Baseline creatinine, electrolytes, FBC, troponin, fluid assessment (POCUS/IVC).
ALBUMIN FIRST — start albumin 1 g/kg/day (max 100 g/day) × 2 days as diagnostic challenge. If no improvement in creatinine AND criteria met → proceed to terlipressin.
TERLIPRESSIN INITIATION — TWO regimens: (a) CONTINUOUS INFUSION (ICU preferred): start 2 mg/24h, titrate up by 1-2 mg/day to max 12 mg/day; lower peak-trough fluctuation, fewer ischaemic events. (b) INTERMITTENT BOLUS (ward): 1 mg IV Q4-6h (up to 2 mg Q4h if no response by day 3), max 12 mg/day.
CONCOMITANT ALBUMIN — day 1: 1 g/kg (max 100 g); from day 2: 20-40 g/day. REDUCE albumin if fluid overload develops (JVP up, pulmonary oedema, weight gain >1 kg/day) — the leading cause of terlipressin-associated respiratory failure.
DAILY MONITORING — serum creatinine (target: fall towards <1.5 mg/dL), MAP (target ≥65 mmHg, rise often seen as splanchnic vasoconstriction), urine output, fluid balance, daily weight. Check for ischaemic side effects: abdominal pain (mesenteric), chest pain/dyspnoea (MI/pulmonary oedema), cold/dusky fingers or toes (digital ischaemia), confusion.
TITRATION — if creatinine FALLS ≥25% in 24h → reduce terlipressin by 50% (response). If creatinine RISES or static at day 3 → increase dose to max. If no response by day 7 → consider treatment failure, switch to noradrenaline or move to RRT.
STOP CRITERIA — (a) SUCCESS: creatinine <1.5 mg/dL (or ↓ ≥50% from baseline) for >24h → taper over 1-2 days. (b) FAILURE: no response after 14 days, or irreversible ischaemia, or need for RRT. (c) RECURRENCE: relapse after stopping (20-50%) → re-treat; if recurrent, consider continuous infusion maintenance.
WHEN TO STOP AND SWITCH — STOP terlipressin if: ischaemic event (new MI, mesenteric/digital ischaemia), uncontrolled fluid overload/pulmonary oedema despite albumin reduction, or persistent respiratory failure. SWITCH to noradrenaline 0.5-3 mg/h infusion (central line, ICU).

[1]

Prevention of HRS — high-risk scenarios

SBP (spontaneous bacterial peritonitis) — give IV albumin 1.5 g/kg on day 1 and 1 g/kg on day 3 to ALL SBP patients with creatinine >1 mg/dL OR bilirubin >4 mg/dL (Sort 1999, NEJM). REDUCES HRS incidence (10% vs 33%) and 90-day mortality (22% vs 41%).
LARGE-VOLUME PARACENTESIS (>5 L) — replace with 6-8 g albumin per litre removed to prevent post-paracentesis circulatory dysfunction (PPCD) which can trigger HRS days later.
AVOID NEPHROTOXINS — no NSAIDs (aspirin, ibuprofen, diclofenac, naproxen, celecoxib — all). Avoid aminoglycosides (gentamicin, tobramycin — high nephrotoxicity in cirrhosis). Use ACE-inhibitors/ARBs and diuretics with caution (reduce or stop if AKI develops). Contrast only if essential.
TREAT PRECIPITANTS PROMPTLY — early broad-spectrum antibiotics for suspected infection, endoscopic therapy for variceal bleed, corticosteroids for severe alcoholic hepatitis (Maddrey >32 with prednisolone 40 mg/day × 28 days), lactulose/rifaximin for hepatic encephalopathy.
BETA-BLOCKERS — clinical judgement — non-selective beta-blockers (propranolol, nadolol, carvedilol) reduce portal pressure and variceal bleeding risk, BUT in advanced cirrhosis with refractory ascites or HRS they may reduce cardiac output and worsen renal perfusion. Mandorfer 2014: beta-blocker cessation in refractory ascites improved survival. STOP if SBP <90, MAP <65, or AKI develops.
LONG-TERM ASCITES CONTROL — sodium restriction (<2 g/day), spironolactone + furosemide (ratio 100:40, titrate slowly), LVP with albumin for refractory ascites, evaluate for TIPS in suitable candidates, refer for liver transplant assessment early.

[1]

Exam practice

SAQ — HRS-AKI in decompensated cirrhosis: terlipressin and albumin

15 minutes · 10 marks

A 56-year-old man with alcohol-related cirrhosis (MELD 27) and tense ascites is admitted with a 4-day history of increasing abdominal distension and oliguria. He has grade 2 hepatic encephalopathy but is obeying commands. He has been on spironolactone 400 mg/day and furosemide 80 mg/day. Examination: BP 96/58 (MAP 67), HR 98, JVP not visible, no ankle oedema, asterixis present. Ascitic tap shows 280 neutrophils/mm³ (SBP, culture pending). Laboratory: creatinine 226 µmol/L (baseline 92 four weeks ago), sodium 128 mmol/L, bilirubin 132 µmol/L, INR 2.1, albumin 24 g/L, urine Na <10 mEq/L, FENa 0.4%, bland urine sediment, normal renal ultrasound. He has had no diuretics today and no nephrotoxins. He received albumin 1.5 g/kg on day 1 and 1 g/kg on day 3 of admission for SBP prophylaxis, plus cefotaxime.

[1]

SAQ — Differentiating HRS from acute tubular necrosis (ATN) in a cirrhotic patient

15 minutes · 10 marks

A 64-year-old woman with hepatitis C cirrhosis and ascites is referred from the ward with AKI 24 hours after an upper GI bleed (haematemesis, Hb fell from 98 to 62 g/L, transfused 4 units). On examination she is cool peripherally, BP 82/50 (MAP 60), HR 116, lactate 4.2 mmol/L, creatinine 268 µmol/L (baseline 95), urine Na 38 mEq/L, FENa 2.8%, urine shows muddy-brown granular casts, normal renal ultrasound. Variceal band ligation has been performed, terlipressin (for variceal bleed) is running, ceftriaxone given. The hepatology team has asked whether she now has HRS-AKI and whether the vasoconstrictor regimen should be escalated.

[1]

Clinical pearls

High-yield HRS points for CICM/FFICM exam

HRS is FUNCTIONAL kidney failure — NOT structural. The kidney is HISTOLOGICALLY NORMAL in HRS (no ATN, no glomerulonephritis, no interstitial nephritis). The problem is: intense RENAL VASOCONSTRICTION (from systemic/splanchnic vasodilation → reduced effective circulating volume → RAAS/sympathetic overactivation → renal vasoconstriction). PROOF: HRS kidney transplanted into a normal recipient → works perfectly. HRS resolves with LIVER transplant (new liver → normal splanchnic haemodynamics → renal vasodilation → recovery).[6]
Albumin challenge (1 g/kg × 48h) is DIAGNOSTIC. Before diagnosing HRS: give ALBUMIN 1 g/kg/day for 2 days. If creatinine IMPROVES (drops to <1.5 or improves by >50%) → NOT HRS (was PRERENAL — volume-responsive). If NO improvement → HRS (if other criteria met). This EXCLUDES simple volume depletion (which mimics HRS).[1]
Terlipressin — CONFIRM trial (2021, NEJM). First FDA-approved therapy for HRS. Terlipressin (vasopressin V1 receptor agonist — splanchnic vasoconstriction → redirects blood to central circulation → improves renal perfusion). CONFIRM trial: terlipressin + albumin vs placebo + albumin. RESULT: HRS reversal 32% vs 17% (p<0.001). CAUTION: respiratory failure (10% vs 2% — fluid overload from albumin). DOSE: 1-2 mg IV Q4-6h or continuous infusion.[2]
Pathophysiology — peripheral arterial vasodilation hypothesis. Cirrhosis → portal hypertension → splanchnic vasodilation (nitric oxide, carbon monoxide → vasodilators increase). RESULT: blood pools in splanchnic circulation → reduced effective arterial blood volume → body perceives 'hypovolaemia' → RAAS + sympathetic + ADH activation → EXTREME renal vasoconstriction (to preserve blood pressure) → GFR drops → AKI. LATE: cardiac dysfunction (cirrhotic cardiomyopathy) worsens. It's a VICIOUS CYCLE of vasodilation → compensation → renal failure.[6]
Common PRECIPITANTS of HRS. HRS is often TRIGGERED by an acute insult in a patient with decompensated cirrhosis: (a) SBP (spontaneous bacterial peritonitis — #1 precipitant — 30% of SBP patients develop HRS). (b) GI bleed (variceal — hypovolaemia). (c) Large-volume paracentesis without albumin replacement (fluid shift). (d) Diuretic-induced (over-diuresis → volume depletion). (e) Alcoholic hepatitis (acute). (f) Sepsis/infection. (g) Nephrotoxic drugs (NSAIDs — AVOID in cirrhosis). PREVENT SBP-HRS: albumin (1.5 g/kg day 1, 1 g/kg day 3) in SBP patients with creatinine >1 or bilirubin >4.[3]
Noradrenaline as alternative to terlipressin. If terlipressin UNAVAILABLE: noradrenaline infusion (0.5-3 mg/h — titrate to MAP and creatinine response). MECHANISM: alpha vasoconstriction → systemic/splanchnic vasoconstriction → improved renal perfusion (similar concept to terlipressin). EVIDENCE: several studies — noradrenaline non-inferior to terlipressin for HRS reversal. ADVANTAGE: widely available (all ICUs have it), titratable, can be used if terlipressin not available. DISADVANTAGE: requires central line, continuous infusion (not bolus), needs ICU monitoring.[3]
HRS vs ATN — critical distinction. HRS: urine Na LOW (<10), FENa LOW (<1%), urine sediment Bland (no casts), normal renal US, NO improvement with albumin alone. ATN: urine Na HIGH (>30), FENa HIGH (>2%), urine sediment: granular casts/muddy brown casts, may have abnormal US (or normal), caused by: sepsis, shock, nephrotoxins. MANAGEMENT DIFFERS: HRS → terlipressin + albumin. ATN → treat cause + RRT (terlipressin won't help ATN).[1]
NSAIDs are CONTRAINDICATED in cirrhosis. NSAIDs inhibit prostaglandins → reduce renal vasodilation (prostaglandins maintain renal perfusion in cirrhosis — RAAS causes vasoconstriction, prostaglandins counterbalance). WITHOUT prostaglandins: unopposed renal vasoconstriction → HRS. PRACTICE: ALL NSAIDs CONTRAINDICATED in cirrhosis with ascites (ibuprofen, diclofenac, naproxen, celecoxib — all). Use: paracetamol for analgesia (safe — up to 2-3 g/day in cirrhosis).[3]
TIPS for HRS — selected patients. TIPS (transjugular intrahepatic portosystemic shunt): stent placed between portal vein and hepatic vein → decompresses portal system → reduces splanchnic vasodilation → improves renal perfusion. EVIDENCE: improves renal function in HRS type 2 (slow) — less evidence for type 1 (acute — too unstable for TIPS). CONTRAINDICATIONS: severe liver failure (MELD >18), severe encephalopathy, severe cardiopulmonary disease, portal vein thrombosis. COMPLICATIONS: hepatic encephalopathy (worsens — shunts ammonia), heart failure (increased preload).[5]
Liver transplant — definitive cure for HRS. HRS is REVERSIBLE with transplant (kidney is histologically normal — function returns once splanchnic haemodynamics normalise). MELD: HRS raises creatinine → MELD increases → higher transplant priority. OUTCOMES: (a) Renal recovery: 60-80% of HRS patients recover renal function post-transplant (may take weeks-months). (b) Temporary RRT: 20-30% need dialysis in first weeks post-transplant (usually temporary). (c) Simultaneous liver-kidney transplant: if HRS prolonged (>12 weeks of RRT before transplant — kidney may not fully recover → may need kidney transplant too).[5]
Albumin in cirrhosis — NOT just for HRS. Albumin has MULTIPLE roles in cirrhosis: (a) ONCOTIC pressure (maintains intravascular volume — cirrhotics are hypoalbuminaemic). (b) BINDING (binds toxins — bilirubin, drugs, endotoxin — reduces systemic inflammation). (c) ANTIOXIDANT (scavenges free radicals). (d) VOLUME EXPANSION (improves effective circulating volume → reduces RAAS). INDICATIONS: SBP (1.5 g/kg + 1 g/kg — reduces HRS, Sort 1999), large-volume paracentesis (>5L: 6-8 g albumin per L removed), HRS (1 g/kg × 2 days diagnostic + 20-40 g/day treatment), hepatorenal prevention. A dose-response meta-analysis (Salerno 2015) confirmed higher albumin dose regimens improve HRS reversal.[1][11]
Cardiac dysfunction in HRS (cirrhotic cardiomyopathy). Cirrhosis → cardiac dysfunction (systolic + diastolic) → contributes to HRS: (a) Systolic: reduced contractile reserve (cannot increase cardiac output in response to stress — exercise, sepsis). (b) Diastolic: stiff LV (impaired relaxation — reduced filling). (c) Electrophysiological: prolonged QT (arrhythmia risk). (d) Result: cardiac output insufficient → renal perfusion compromised → HRS. DIAGNOSIS: echocardiography (stress echo for systolic reserve, tissue Doppler for diastolic). MANAGEMENT: treat underlying cirrhosis (transplant resolves cardiomyopathy).[6]
HRS recurrence and relapse. After terlipressin successfully reverses HRS: RELAPSE occurs in ~20-50% (within 2 weeks of stopping). MANAGEMENT: (a) RETREAT with terlipressin + albumin (may work again). (b) If recurrent: consider continuous terlipressin (or noradrenaline infusion). (c) TIPS (if suitable). (d) URGENT liver transplant (HRS will recur until liver transplant). GOAL of medical therapy: BRIDGE to transplant (terlipressin buys time — but doesn't cure — transplant is definitive).[2]
Acute kidney injury in cirrhosis — ADQI classification. Modern approach (ADQI-ISSN 2024): AKI in cirrhosis = creatinine ≥0.3 mg/dL (26.5 μmol/L) in 48h OR ≥50% rise from baseline in 7d. STAGES: Stage 1: 1.5-2.0x baseline. Stage 2: 2.0-3.0x. Stage 3: >3.0x OR RRT OR creatinine >4.0. MANAGEMENT: (a) Stage 1: identify cause, stop nephrotoxins, albumin if volume-depleted. (b) Stage 2: albumin challenge (1 g/kg × 2d — diagnostic). (c) Stage 3: terlipressin if HRS, RRT if refractory, transplant evaluation.[1]
Modern HRS classification — HRS-AKI, HRS-AKD, HRS-CKD (ADQI-iICA 2024). The old type 1/type 2 split is obsolete. NEW classification by TIME COURSE: (a) HRS-AKI: rise of ≥0.3 mg/dL (26.5 μmol/L) in 48h OR ≥50% rise in 7 days (formerly type 1). (b) HRS-AKD (acute kidney disease): AKI criteria not met but creatinine >1.5 mg/dL for <90 days (formerly type 2 — refractory ascites, slow course). (c) HRS-CKD: eGFR <60 for >90 days (chronic, overlaps with CKD of cirrhosis). Key: ALL still require the same ICA diagnostic criteria (no shock, no nephrotoxins, no structural disease, no albumin response).[3]
Confirms criteria and sub-criteria — the albumin challenge details. HRS-AKI requires NO response to albumin challenge of 1 g/kg/day (max 100 g) × 2 consecutive days. Response = decrease of creatinine to <1.5 mg/dL OR ≥50% reduction. Recent consensus ALSO now accepts HRS-AKI diagnosis in patients on diuretics who STILL meet all criteria (old criteria required diuretic cessation first). Serum creatinine UNDERESTIMATES GFR in cirrhosis (low muscle mass, low bilirubin interference) — always interpret cautiously; a cystatin C-based eGFR may be more accurate.[1]
Predictors of response to terlipressin. WHO responds? BETTER response: baseline creatinine <5 mg/dL, serum bilirubin <10 mg/dL, higher MAP, younger age, early initiation (within 7 days of diagnosis). POOR response: baseline creatinine >5 mg/dL (response rate <20%), ACLF grade 3, concomitant sepsis/ATN, hyponatraemia <125. PRACTICE: don't withhold terlipressin based on a single poor predictor, but counsel about reduced response in advanced disease and have a low threshold to switch to noradrenaline or move to RRT if no response by day 4-5.[10]
AKI stage reduction predicts survival (Wong 2020). In CONFIRM and REVERSE pooled analysis, every stage reduction of AKI (per KDIGO) was associated with a ~30% reduction in mortality. HRS reversal (creatinine <1.5) is a SURROGATE for survival benefit even though CONFIRM did not show a statistically significant survival difference at 90 days. IMPLICATION: aim for HRS reversal — it matters even if 90-day survival curves overlap in a single trial.[10]
NGAL and urinary biomarkers — distinguishing HRS from ATN. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is the most studied biomarker. ATN: urinary NGAL HIGH (>220 μg/g creatinine). HRS: urinary NGAL LOW (<100). CUT-OFF around 100-200 μg/g discriminates. CLINICAL USE: helps when FENa and urine Na are confounded (diuretics, AKI), but NOT yet in routine practice in most ICUs — terlipressin trial can be the de-facto discriminator (responds → HRS; no response → ATN).[3]
Terlipressin ischaemic adverse effects — clinical vigilance. CONFIRM trial: serious adverse events leading to discontinuation in 11% vs 2% placebo. ISCHAEMIC EVENTS (overall ~4-12%): MI (rare but reported), mesenteric ischaemia (abdominal pain, lactate rise), digital ischaemia (cold/dusky fingers — reversible on stopping), skin necrosis at infusion site (extravasation). RISK FACTORS: high dose (>8 mg/day bolus), peripheral vascular disease, age >65. PREVENTION: continuous infusion (smoother profile), titrate carefully, stop at first sign of ischaemia.[2]
Respiratory failure — the silent killer of terlipressin therapy. In CONFIRM: respiratory failure 11% terlipressin vs 2% placebo (p=0.01). MECHANISM: not direct lung toxicity — it is FLUID OVERLOAD from concomitant albumin plus improved renal perfusion PLUS splanchnic vasoconstriction redirecting volume centrally. PREVENTION: (a) reduce albumin if patient gains >1 kg/day or develops pulmonary oedema; (b) daily fluid balance, JVP/POCUS/IVC assessment; (c) consider diuretics once renal function improves. This is WHY terlipressin in ICU with close monitoring outperforms ward-based bolus regimens.[2]
Simultaneous liver-kidney (SLK) transplant criteria. HRS is reversible BUT if renal failure is prolonged, the kidney may not recover even after liver transplant. SLK criteria (OPTN 2017, applicable in HRS): dialysis ≥6 weeks WITH evidence of CKD (eGFR <60 for ≥90 days); OR sustained AKI requiring dialysis ≥6 weeks pre-transplant. The 6-week rule is the practical threshold: if HRS patient is on RRT >6 weeks before transplant, evaluate for SLK. RECOVERY: even after SLK, the native kidney may recover in up to 30%, making delayed native-nephrectomy decisions complex.[5]
HRS in acute-on-chronic liver failure (ACLF). ACLF is cirrhosis + acute decompensation + organ failure(s) (CLIF-C ACLF score). HRS-AKI is COMMON in ACLF and often coexists with infection, shock, ATN — pure HRS is rarer than in stable cirrhosis. PRACTICE: in ACLF, often BOTH HRS and ATN coexist (mixed picture). MANAGE: treat infection aggressively, give terlipressin + albumin (lower threshold), expect lower response rates in ACLF grade 3 (~25% response vs ~50% in grade 1). MELD/CLIF scores guide transplant urgency.[5]
Continuous vs intermittent terlipressin. CONTINUOUS INFUSION (2-12 mg/24h): smoother haemodynamics, FEWER ischaemic events, ICU setting, easier titration, slightly higher efficacy in some studies. INTERMITTENT BOLUS (1-2 mg Q4-6h): ward-based, cheaper in nursing time, more peak-related ischaemia, more respiratory failure in CONFIRM (which used bolus). PRACTICE: ICU patient → continuous infusion; ward patient → bolus with close monitoring; SWITCH to continuous if dose escalation needed or ischaemic concerns.[2]
HRS-AKI precipitated by SBP — Sort 1999 landmark trial. Before albumin use, 33% of SBP patients developed HRS. Sort 1999 NEJM: albumin 1.5 g/kg day 1 + 1 g/kg day 3 in high-risk SBP (creatinine >1, bilirubin >4) → HRS 10% vs 33%, 90-day mortality 22% vs 41%. This is the highest-impact intervention in cirrhosis AKI. PRACTICE: ALWAYS give albumin to SBP with renal/bilirubin criteria — no exception. NOT indicated in low-risk SBP (normal creatinine/bilirubin) — no benefit.[7]
Octreotide + midodrine — the weak alternative. Mechanism: octreotide (somatostatin analogue) inhibits splanchnic vasodilators; midodrine (alpha-1 agonist) raises systemic vascular resistance. EVIDENCE: Cavallin 2015 RCT (Hepatology) — terlipressin + albumin SUPERIOR to octreotide + midodrine + albumin (HRS reversal ~50% vs ~15%). Indicated ONLY when terlipressin and noradrenaline BOTH unavailable (rare in ICU). DOSE: octreotide 100-200 mcg SC TDS + midodrine 2.5-7.5 mg PO TDS, titrate to MAP rise of 15 mmHg. CAUTION: not appropriate for ICU patients — go straight to terlipressin/noradrenaline.[8]
Noradrenaline vs terlipressin — head-to-head evidence. Alessandria 2007 (J Hepatol, n=22): noradrenaline (0.1-0.7 mg/h titrated) vs terlipressin — noradrenaline non-inferior for HRS reversal (83% vs 43%, p=0.05) with fewer serious adverse events. Subsequent meta-analyses (Jiang 2023, Ghosh 2013) confirm non-inferiority of noradrenaline. PRACTICE: noradrenaline is the ICU first-line when terlipressin unavailable OR when high ischaemic risk OR when continuous titration is needed. Cost-saving: noradrenaline is dramatically cheaper than terlipressin. LIMITATION: requires central line + ICU bed (not feasible on the ward).[9]
Splanchnic pathophysiology — molecular drivers. The vasodilation cascade: portal hypertension → shear stress + bacterial translocation → upregulation of nitric oxide synthase (eNOS, iNOS) in splanchnic endothelium, increased CO (carbon monoxide from haem oxygenase), endocannabinoids, glucagon, calcitonin gene-related peptide (CGRP). NET EFFECT: massive splanchnic vasodilation, low systemic vascular resistance (SVR), high cardiac output (hyperdynamic circulation). The body senses a 'low effective arterial volume' and mounts the classic compensatory response: RAAS, SNS, non-osmotic ADH — causing intense renal vasoconstriction + sodium/water retention (ascites, dilutional hyponatraemia).[1]
Refractory HRS and RRT as bridge. When terlipressin + albumin FAILS (no response by day 7-14, or progressing ACLF): start RRT as BRIDGE to transplant (NOT destination therapy — HRS without transplant is universally fatal). MODALITY: CRRT (CVVHDF) preferred in haemodynamically unstable cirrhotics; SLED as alternative; intermittent HD only if stable. ANTICOAGULATION: citrate preferred (regional anticoagulation, no systemic effect, less bleeding) — but WATCH calcium (citrate toxicity) and the risk of citrate accumulation in severe liver failure (use heparin instead). TIMING: refer URGENTLY for transplant; HRS-on-RRT >6 weeks → consider SLK.[5]

Red flags

Critical HRS red flags

HRS-AKI: mortality 80% at 2 weeks UNTREATED — rapid diagnosis and treatment essential.[1]
Albumin challenge (1 g/kg × 48h) is DIAGNOSTIC — no improvement → HRS.[1]
Terlipressin + albumin — CONFIRM trial: first FDA-approved (32% reversal).[2]
NSAIDs CONTRAINDICATED in cirrhosis (worsen HRS).[3]
SBP is #1 precipitant — prophylactic albumin (1.5/1 g/kg) reduces HRS.[1]
Liver transplant is DEFINITIVE — HRS is reversible (functional, not structural).[5]
Type 1 HRS median survival ~2 weeks UNTREATED — every hour counts; initiate albumin challenge immediately on admission.[1]
Terlipressin RESPIRATORY FAILURE (11% in CONFIRM) — fluid overload from albumin; reduce albumin if weight gain >1 kg/day or pulmonary oedema.[2]
Terlipressin ISCHAEMIC events (MI, mesenteric, digital — 4-12%) — STOP at first sign; continuous infusion safer than bolus.[2]
ALL NSAIDs and aminoglycosides CONTRAINDICATED in cirrhotic ascites — cause or worsen HRS.[5]
Beta-blockers may HARM in refractory ascites/HRS — STOP if SBP <90, MAP <65, or AKI develops (Mandorfer 2014).[6]
HRS on RRT >6 weeks → evaluate for simultaneous liver-kidney transplant — native kidney may not recover.[5]

Prognosis

CONFIRM trial (Wong 2021, NEJM) — terlipressin for HRS

RCT: 300 patients with HRS type 1. Terlipressin + albumin vs placebo + albumin.

Primary outcome (HRS reversal — 2 consecutive creatinine ≤1.5 mg/dL, ≥2h apart, without RRT, ≥10 days):
- Terlipressin: 32% (vs placebo 17%, p=0.006 — SIGNIFICANT)
Need for RRT at day 90: 28% vs 32% (NS — trend favouring terlipressin)
Survival at day 90: 51% vs 45% (NS — no survival benefit)
Respiratory failure: 11% vs 2% (p=0.01 — MORE with terlipressin — from fluid overload/albumin)
CONCLUSION: Terlipressin improves HRS reversal (32% vs 17%) but does NOT improve survival. Caution: respiratory failure (fluid overload). First FDA-approved HRS therapy. [1]

UNTREATED HRS type 1: median survival ~2 weeks (80% mortality at 2 weeks). WITH terlipressin: may reverse HRS (32%) — buys time for transplant. WITH liver transplant: renal recovery 60-80% (HRS is reversible — functional kidney failure). Simultaneous liver-kidney transplant: if HRS prolonged (>12 weeks RRT — kidney may not recover).

[1]

REVERSE trial (Boyer 2016, Gastroenterology) — terlipressin for HRS-1

RCT: 178 patients with HRS type 1. Terlipressin + albumin vs placebo + albumin. Terlipressin 1 mg IV Q6h (titrated to 2 mg Q6h from day 4 if no response), albumin 25 g/day.

Primary outcome (HRS reversal — 2 consecutive creatinine ≤1.5 mg/dL ≥2h apart):
- Terlipressin: 19% (vs placebo 13%, p=NS — NOT significant in ITT analysis)
Per-protocol/verified HRS-1 subset: 23% vs 13% (p<0.05)
RRT need: 28% vs 32% (NS)
Survival at day 90: 51% vs 47% (NS)
CONCLUSION: REVERSE was NEUTRAL in the primary analysis — underpowered and confounded by inclusion of non-HRS AKI (~30% misclassified). Pooled with CONFIRM, it supports terlipressin efficacy in confirmed HRS-1. Established the importance of STRICT diagnostic criteria (albumin challenge mandatory) before enrolment.[4]

Cavallin 2015 (Hepatology) — terlipressin vs octreotide/midodrine for HRS

RCT: 78 patients with HRS (type 1 and 2). Terlipressin + albumin vs octreotide + midodrine + albumin.

Terlipressin: 1-2 mg IV Q12h; octreotide: 100-200 mcg SC TDS; midodrine: 2.5-7.5 mg PO TDS; all + albumin 20-40 g/day.
Primary outcome (sustained HRS reversal — creatinine <1.5 mg/dL without RRT):
- Terlipressin: 50% (vs octreotide/midodrine 14%, p=0.009 — SIGNIFICANT)
Recurrence: 25% vs 67% (terlipressin lower)
Survival: NS between groups
CONCLUSION: Terlipressin is SUPERIOR to the octreotide + midodrine combination. Octreotide + midodrine is a last-resort regimen ONLY when vasoconstrictor alternatives are unavailable. This trial solidified terlipressin (and noradrenaline) as the preferred agents.[8]

Sort 1999 (NEJM) — albumin in SBP prevents HRS

RCT: 126 patients with cirrhosis and SBP. IV albumin + antibiotics vs antibiotics alone. Albumin 1.5 g/kg day 1 + 1 g/kg day 3 in patients at risk (creatinine >1 mg/dL or bilirubin >4 mg/dL).

Primary outcomes:
- HRS incidence: 10% (albumin) vs 33% (controls, p=0.007)
- 3-month mortality: 22% vs 41% (p=0.03)
- Renal impairment: 13% vs 38% (p=0.002)
CONCLUSION: IV albumin in high-risk SBP HALVES HRS incidence and improves survival. This is the foundational evidence for the universal recommendation of albumin in SBP with renal/bilirubin criteria — a landmark in hepatology and a cornerstone of HRS PREVENTION.[7]

Alessandria 2007 (J Hepatol) — noradrenaline vs terlipressin

RCT: 22 patients with HRS-1/2. Noradrenaline infusion vs terlipressin bolus + albumin.

Noradrenaline: 0.1-0.7 mg/h titrated to MAP; terlipressin: 1-2 mg Q12h.
Primary outcome (HRS reversal):
- Noradrenaline: 83% (vs terlipressin 43%, p=0.05)
Recurrence: similar
Adverse events: fewer serious ischaemic events with noradrenaline
CONCLUSION: PILOT study (small, unblinded) — noradrenaline appeared NON-INFERIOR (and in this small sample, possibly superior) to terlipressin, with fewer ischaemic events. Subsequent meta-analyses (Ghosh 2013, Jiang 2023, n>500) confirm non-inferiority. PRACTICE: noradrenaline is a legitimate ICU first-line alternative — cheaper, more available, smoother titration, requires central line.[9]

Wong 2020 (NDT) — AKI stage reduction predicts survival in HRS-1

Pooled analysis of CONFIRM + REVERSE (n=466). Tested whether REDUCTION in AKI stage (per KDIGO) predicts survival.

Primary finding: For every AKI stage reduction, mortality fell ~30% (HR 0.70, p<0.01).
HRS reversal (creatinine <1.5): 90-day survival 70% (reversal) vs 38% (no reversal, p<0.001).
CONCLUSION: HRS reversal IS a meaningful surrogate for survival — the lack of statistically significant survival benefit in CONFIRM alone was a power issue, not a lack of biological benefit. REINFORCES the goal of treatment: achieve HRS reversal (terlipressin + albumin, escalate to max dose, switch to noradrenaline if failing).[10]

Exam pitfalls

Trap: 'HRS kidney is structurally damaged' → FALSE. The kidney is HISTOLOGICALLY NORMAL in HRS. It is a FUNCTIONAL/vasomotor syndrome — proof: HRS kidney transplanted into a healthy recipient functions normally; HRS resolves with liver transplant.
Trap: 'Diuretics must be stopped before HRS diagnosis' → OLD criteria. The ADQI-iICA 2024 consensus ALLOWS HRS diagnosis while on diuretics if all other criteria are met.
Trap: 'FENa <1% rules out ATN' → FALSE. FENa is unreliable in cirrhosis (diuretics, low sodium intake, low GFR). Urinary NGAL and the response to terlipressin are better discriminators.
Trap: 'HRS and ATN are mutually exclusive' → FALSE. In ACLF, sepsis, and ICU patients, MIXED HRS + ATN is common — treat both (terlipressin + albumin AND treat the precipitating cause).
Trap: 'Terlipressin improves survival in HRS' → NUANCED. CONFIRM did NOT show a statistically significant 90-day survival benefit, BUT pooled data (Wong 2020) show reversal reduces mortality ~30% per stage. The trial endpoint (reversal) IS clinically meaningful.
Trap: 'Albumin challenge for HRS = 1.5 g/kg' → FALSE. The HRS DIAGNOSTIC albumin challenge is 1 g/kg/day (max 100 g) × 2 days. The SBP PROPHYLAXIS albumin regimen is 1.5 g/kg day 1 + 1 g/kg day 3 — DIFFERENT doses for DIFFERENT purposes.
Trap: 'Type 2 HRS = stable, treat as outpatient' → PARTLY TRUE. Type 2 (now HRS-AKD) is slower, BUT mortality at 6 months is still ~70% untreated — refer for transplant early; TIPS may help selected patients.
Trap: 'TIPS is contraindicated in HRS because of encephalopathy' → OVERSIMPLIFIED. TIPS is CONTRAINDICATED in severe encephalopathy (and MELD >18, severe cardiopulmonary disease), but it is a valid option in selected HRS-AKD patients with refractory ascites.
Trap: 'HRS recurs after transplant so transplant doesn't help' → FALSE. HRS resolves in 60-80% after liver transplant (functional kidney failure recovers). Recurrence after terlipressin is common (20-50%) — that's why transplant (not just terlipressin) is the definitive cure. [1]

References

[1]Angeli P, Garcia-Tsao G, Nadim MK, et al. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document J Hepatol, 2019.PMID 31302175
[2]Wong F, Pappas SC, Curry MP, et al. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome N Engl J Med, 2021.PMID 33657294
[3]Nadim MK, Kellum JA, Forni L, et al. Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting J Hepatol, 2024.PMID 38527522
[4]Boyer TD, Sanyal AJ, Wong F, et al. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1 Gastroenterology, 2016.PMID 26896734
[5]Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases Hepatology, 2021.PMID 33942342
[6]Bucsics T, Schwabl P, Mandorfer M, et al. The trigger matters - outcome of hepatorenal syndrome vs. specifically triggered acute kidney injury in cirrhotic patients with ascites Liver Int, 2016.PMID 27169985
[7]Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis N Engl J Med, 1999.PMID 10432325
[8]Cavallin M, Kamath PS, Merli M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial Hepatology, 2015.PMID 25644760
[9]Alessandria C, Ottobrelli A, Debernardi-Venon W, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study J Hepatol, 2007.PMID 17560680
[10]Wong F, Boyer TD, Sanyal AJ, et al. Reduction in acute kidney injury stage predicts survival in patients with type-1 hepatorenal syndrome Nephrol Dial Transplant, 2020.PMID 30887050
[11]Salerno F, Navickis RJ, Wilkes MM. Albumin treatment regimen for type 1 hepatorenal syndrome: a dose-response meta-analysis BMC Gastroenterol, 2015.PMID 26606982

[1]

HRS Type 1 (AKI) vs Type 2 (AKD)

Feature	Type 1 (HRS-AKI)	Type 2 (HRS-AKD)
Onset	RAPID (doubling creatinine <2 weeks)	SLOW (weeks-months)
Creatinine	>2.5 mg/dL (220 μmol/L)	1.5-2.5 mg/dL (133-220 μmol/L)
Clinical	Acute deterioration, often precipitant	Stable, refractory ascites
Mortality (untreated)	80% at 2 WEEKS	70% at 6 MONTHS
Treatment	Terlipressin + albumin → urgent transplant	TIPS, albumin, transplant (elective)
Natural history	Days-weeks (death from multi-organ failure)	Months (death from renal failure/ascites)

[1]

HRS-AKI vs prerenal AKI vs ATN — diagnostic differentiation

Feature	Prerenal AKI	HRS-AKI	ATN (intrinsic)
Mechanism	True volume depletion	Functional vasomotor (splanchnic vasodilation)	Tubular injury (ischaemic/toxic)
Urine Na	<20 mEq/L	<10 mEq/L (very low)	>30 mEq/L
FENa	<1%	<1%	>2%
Urine sediment	Bland	Bland (no casts)	Muddy-brown granular casts
Urine osm	>500	>500	Isotonic (~300)
Response to albumin	YES (creatinine falls)	NO (the defining test)	NO
Renal US	Normal	Normal	Normal (or in chronic CKD)
Proteinuria	None	<500 mg/day	Variable
Treatment	Volume (saline/albumin)	Terlipressin + albumin	Treat cause, RRT
Histology	Normal	NORMAL (functional)	Tubular necrosis

[1]

Terlipressin vs noradrenaline vs octreotide/midodrine — vasoconstrictor comparison

Feature	Terlipressin	Noradrenaline	Octreotide + Midodrine
Mechanism	V1 vasopressin agonist (splanchnic)	alpha-1 agonist (systemic + splanchnic)	Octreotide = somatostatin analogue; midodrine = alpha-1 agonist
FDA-approved for HRS	YES (2022, first agent)	No (off-label)	No (off-label, weak)
Route	IV bolus Q4-6h or continuous infusion	Continuous IV infusion (central line)	SC octreotide + PO midodrine
Dose	1-2 mg Q4-6h or 2-12 mg/day infusion	0.5-3 mg/h titrate to MAP	Octreotide 100-200 mcg SC TDS + midodrine 2.5-7.5 mg PO TDS
Efficacy (HRS reversal)	32-50% (CONFIRM, REVERSE)	40-50% (non-inferior to terlipressin)	LOWEST — ~15-25%
Setting	Ward or ICU; ICU for continuous infusion	ICU only (central line, titration)	Ward (oral/SC), last-resort
Main adverse effect	Ischaemia (MI, mesenteric, digital), respiratory failure (fluid overload)	Peripheral/renal ischaemia, arrhythmia	Bradycardia, hypertension, diarrhoea
Cost/availability	Expensive; not universally available	Cheap; every ICU	Cheap; widely available
Evidence	CONFIRM (n=300), REVERSE (n=178)	Alessandria 2007 pilot (n=22); multiple meta-analyses show non-inferiority	Cavallin 2015 RCT — INFERIOR to terlipressin

[1]

Diagnosis and management of hepatorenal syndrome

SUSPECT HRS — cirrhotic patient with ascites develops AKI (creatinine rise ≥26.5 μmol/L in 48h or ≥1.5x baseline). VERY COMMON in decompensated cirrhosis
EXCLUDE other causes of AKI — (a) Volume depletion (diuretics, diarrhoea, GI bleed) — give ALBUMIN 1 g/kg/day × 2 days. If creatinine improves → prerenal (NOT HRS). (b) ATN (sepsis, hypotension, nephrotoxins) — check urine sediment (granular casts → ATN), urine Na (>30 → ATN), FENa (>2% → ATN). (c) Glomerulonephritis (proteinuria >500, haematuria). (d) Obstruction (renal ultrasound)
ICA 2015 CRITERIA for HRS-AKI (ALL must be met): (a) Cirrhosis + ascites. (b) Creatinine >1.5 mg/dL (133 μmol/L). (c) NO improvement after albumin (1 g/kg/day × 48h). (d) NO shock. (e) NO nephrotoxic drugs. (f) NO structural kidney disease (normal urine sediment, proteinuria <500, normal renal US)
TREATMENT — TERLIPRESSIN + ALBUMIN — (a) Terlipressin: 1-2 mg IV every 4-6h (or continuous infusion 2-12 mg/day). CONFIRM trial: 32% HRS reversal vs 17% placebo. FIRST FDA-approved for HRS. (b) Albumin: 20-40 g/day (maintains intravascular volume, improves splanchnic vasoconstriction effect). (c) Duration: until creatinine <1.5 or 14 days max. (d) MONITOR: creatinine, BP, fluid status. (e) CAUTION: ischaemic side effects (MI, mesenteric, digital — 4%), fluid overload
ALTERNATIVES — (a) Noradrenaline infusion (alternative vasoconstrictor — 0.5-3 mg/h — if terlipressin unavailable). (b) Octreotide + midodrine (LESS effective — only if no terlipressin/noradrenaline). (c) TIPS (transjugular intrahepatic portosystemic shunt — for selected, stable patients). (d) RRT (if refractory — bridge to transplant)
LIVER TRANSPLANT — definitive — HRS is REVERSIBLE with transplant (kidney function recovers — functional, not structural). PRIORITY: MELD score (HRS raises MELD → higher priority). Post-transplant: renal recovery in 60-80% (may need temporary RRT in 20-30%)

[1]

Terlipressin dosing and titration protocol (continuous infusion preferred in ICU)

BASELINE WORKUP — confirm HRS-AKI (ICA criteria), check ECG (terlipressin can prolong QT), review contraindications (ischaemic heart disease, peripheral vascular disease, uncontrolled arrhythmia — relative cautions, weigh benefit vs risk). Baseline creatinine, electrolytes, FBC, troponin, fluid assessment (POCUS/IVC).
ALBUMIN FIRST — start albumin 1 g/kg/day (max 100 g/day) × 2 days as diagnostic challenge. If no improvement in creatinine AND criteria met → proceed to terlipressin.
TERLIPRESSIN INITIATION — TWO regimens: (a) CONTINUOUS INFUSION (ICU preferred): start 2 mg/24h, titrate up by 1-2 mg/day to max 12 mg/day; lower peak-trough fluctuation, fewer ischaemic events. (b) INTERMITTENT BOLUS (ward): 1 mg IV Q4-6h (up to 2 mg Q4h if no response by day 3), max 12 mg/day.
CONCOMITANT ALBUMIN — day 1: 1 g/kg (max 100 g); from day 2: 20-40 g/day. REDUCE albumin if fluid overload develops (JVP up, pulmonary oedema, weight gain >1 kg/day) — the leading cause of terlipressin-associated respiratory failure.
DAILY MONITORING — serum creatinine (target: fall towards <1.5 mg/dL), MAP (target ≥65 mmHg, rise often seen as splanchnic vasoconstriction), urine output, fluid balance, daily weight. Check for ischaemic side effects: abdominal pain (mesenteric), chest pain/dyspnoea (MI/pulmonary oedema), cold/dusky fingers or toes (digital ischaemia), confusion.
TITRATION — if creatinine FALLS ≥25% in 24h → reduce terlipressin by 50% (response). If creatinine RISES or static at day 3 → increase dose to max. If no response by day 7 → consider treatment failure, switch to noradrenaline or move to RRT.
STOP CRITERIA — (a) SUCCESS: creatinine <1.5 mg/dL (or ↓ ≥50% from baseline) for >24h → taper over 1-2 days. (b) FAILURE: no response after 14 days, or irreversible ischaemia, or need for RRT. (c) RECURRENCE: relapse after stopping (20-50%) → re-treat; if recurrent, consider continuous infusion maintenance.
WHEN TO STOP AND SWITCH — STOP terlipressin if: ischaemic event (new MI, mesenteric/digital ischaemia), uncontrolled fluid overload/pulmonary oedema despite albumin reduction, or persistent respiratory failure. SWITCH to noradrenaline 0.5-3 mg/h infusion (central line, ICU).

[1]

Prevention of HRS — high-risk scenarios

SBP (spontaneous bacterial peritonitis) — give IV albumin 1.5 g/kg on day 1 and 1 g/kg on day 3 to ALL SBP patients with creatinine >1 mg/dL OR bilirubin >4 mg/dL (Sort 1999, NEJM). REDUCES HRS incidence (10% vs 33%) and 90-day mortality (22% vs 41%).
LARGE-VOLUME PARACENTESIS (>5 L) — replace with 6-8 g albumin per litre removed to prevent post-paracentesis circulatory dysfunction (PPCD) which can trigger HRS days later.
AVOID NEPHROTOXINS — no NSAIDs (aspirin, ibuprofen, diclofenac, naproxen, celecoxib — all). Avoid aminoglycosides (gentamicin, tobramycin — high nephrotoxicity in cirrhosis). Use ACE-inhibitors/ARBs and diuretics with caution (reduce or stop if AKI develops). Contrast only if essential.
TREAT PRECIPITANTS PROMPTLY — early broad-spectrum antibiotics for suspected infection, endoscopic therapy for variceal bleed, corticosteroids for severe alcoholic hepatitis (Maddrey >32 with prednisolone 40 mg/day × 28 days), lactulose/rifaximin for hepatic encephalopathy.
BETA-BLOCKERS — clinical judgement — non-selective beta-blockers (propranolol, nadolol, carvedilol) reduce portal pressure and variceal bleeding risk, BUT in advanced cirrhosis with refractory ascites or HRS they may reduce cardiac output and worsen renal perfusion. Mandorfer 2014: beta-blocker cessation in refractory ascites improved survival. STOP if SBP <90, MAP <65, or AKI develops.
LONG-TERM ASCITES CONTROL — sodium restriction (<2 g/day), spironolactone + furosemide (ratio 100:40, titrate slowly), LVP with albumin for refractory ascites, evaluate for TIPS in suitable candidates, refer for liver transplant assessment early.

[1]

Exam practice

SAQ — HRS-AKI in decompensated cirrhosis: terlipressin and albumin

15 minutes · 10 marks

[1]

SAQ — Differentiating HRS from acute tubular necrosis (ATN) in a cirrhotic patient

15 minutes · 10 marks

[1]

Clinical pearls

High-yield HRS points for CICM/FFICM exam

HRS is FUNCTIONAL kidney failure — NOT structural. The kidney is HISTOLOGICALLY NORMAL in HRS (no ATN, no glomerulonephritis, no interstitial nephritis). The problem is: intense RENAL VASOCONSTRICTION (from systemic/splanchnic vasodilation → reduced effective circulating volume → RAAS/sympathetic overactivation → renal vasoconstriction). PROOF: HRS kidney transplanted into a normal recipient → works perfectly. HRS resolves with LIVER transplant (new liver → normal splanchnic haemodynamics → renal vasodilation → recovery).[6]
Albumin challenge (1 g/kg × 48h) is DIAGNOSTIC. Before diagnosing HRS: give ALBUMIN 1 g/kg/day for 2 days. If creatinine IMPROVES (drops to <1.5 or improves by >50%) → NOT HRS (was PRERENAL — volume-responsive). If NO improvement → HRS (if other criteria met). This EXCLUDES simple volume depletion (which mimics HRS).[1]
Terlipressin — CONFIRM trial (2021, NEJM). First FDA-approved therapy for HRS. Terlipressin (vasopressin V1 receptor agonist — splanchnic vasoconstriction → redirects blood to central circulation → improves renal perfusion). CONFIRM trial: terlipressin + albumin vs placebo + albumin. RESULT: HRS reversal 32% vs 17% (p<0.001). CAUTION: respiratory failure (10% vs 2% — fluid overload from albumin). DOSE: 1-2 mg IV Q4-6h or continuous infusion.[2]
Pathophysiology — peripheral arterial vasodilation hypothesis. Cirrhosis → portal hypertension → splanchnic vasodilation (nitric oxide, carbon monoxide → vasodilators increase). RESULT: blood pools in splanchnic circulation → reduced effective arterial blood volume → body perceives 'hypovolaemia' → RAAS + sympathetic + ADH activation → EXTREME renal vasoconstriction (to preserve blood pressure) → GFR drops → AKI. LATE: cardiac dysfunction (cirrhotic cardiomyopathy) worsens. It's a VICIOUS CYCLE of vasodilation → compensation → renal failure.[6]
Common PRECIPITANTS of HRS. HRS is often TRIGGERED by an acute insult in a patient with decompensated cirrhosis: (a) SBP (spontaneous bacterial peritonitis — #1 precipitant — 30% of SBP patients develop HRS). (b) GI bleed (variceal — hypovolaemia). (c) Large-volume paracentesis without albumin replacement (fluid shift). (d) Diuretic-induced (over-diuresis → volume depletion). (e) Alcoholic hepatitis (acute). (f) Sepsis/infection. (g) Nephrotoxic drugs (NSAIDs — AVOID in cirrhosis). PREVENT SBP-HRS: albumin (1.5 g/kg day 1, 1 g/kg day 3) in SBP patients with creatinine >1 or bilirubin >4.[3]
Noradrenaline as alternative to terlipressin. If terlipressin UNAVAILABLE: noradrenaline infusion (0.5-3 mg/h — titrate to MAP and creatinine response). MECHANISM: alpha vasoconstriction → systemic/splanchnic vasoconstriction → improved renal perfusion (similar concept to terlipressin). EVIDENCE: several studies — noradrenaline non-inferior to terlipressin for HRS reversal. ADVANTAGE: widely available (all ICUs have it), titratable, can be used if terlipressin not available. DISADVANTAGE: requires central line, continuous infusion (not bolus), needs ICU monitoring.[3]
HRS vs ATN — critical distinction. HRS: urine Na LOW (<10), FENa LOW (<1%), urine sediment Bland (no casts), normal renal US, NO improvement with albumin alone. ATN: urine Na HIGH (>30), FENa HIGH (>2%), urine sediment: granular casts/muddy brown casts, may have abnormal US (or normal), caused by: sepsis, shock, nephrotoxins. MANAGEMENT DIFFERS: HRS → terlipressin + albumin. ATN → treat cause + RRT (terlipressin won't help ATN).[1]
NSAIDs are CONTRAINDICATED in cirrhosis. NSAIDs inhibit prostaglandins → reduce renal vasodilation (prostaglandins maintain renal perfusion in cirrhosis — RAAS causes vasoconstriction, prostaglandins counterbalance). WITHOUT prostaglandins: unopposed renal vasoconstriction → HRS. PRACTICE: ALL NSAIDs CONTRAINDICATED in cirrhosis with ascites (ibuprofen, diclofenac, naproxen, celecoxib — all). Use: paracetamol for analgesia (safe — up to 2-3 g/day in cirrhosis).[3]
TIPS for HRS — selected patients. TIPS (transjugular intrahepatic portosystemic shunt): stent placed between portal vein and hepatic vein → decompresses portal system → reduces splanchnic vasodilation → improves renal perfusion. EVIDENCE: improves renal function in HRS type 2 (slow) — less evidence for type 1 (acute — too unstable for TIPS). CONTRAINDICATIONS: severe liver failure (MELD >18), severe encephalopathy, severe cardiopulmonary disease, portal vein thrombosis. COMPLICATIONS: hepatic encephalopathy (worsens — shunts ammonia), heart failure (increased preload).[5]
Liver transplant — definitive cure for HRS. HRS is REVERSIBLE with transplant (kidney is histologically normal — function returns once splanchnic haemodynamics normalise). MELD: HRS raises creatinine → MELD increases → higher transplant priority. OUTCOMES: (a) Renal recovery: 60-80% of HRS patients recover renal function post-transplant (may take weeks-months). (b) Temporary RRT: 20-30% need dialysis in first weeks post-transplant (usually temporary). (c) Simultaneous liver-kidney transplant: if HRS prolonged (>12 weeks of RRT before transplant — kidney may not fully recover → may need kidney transplant too).[5]
Albumin in cirrhosis — NOT just for HRS. Albumin has MULTIPLE roles in cirrhosis: (a) ONCOTIC pressure (maintains intravascular volume — cirrhotics are hypoalbuminaemic). (b) BINDING (binds toxins — bilirubin, drugs, endotoxin — reduces systemic inflammation). (c) ANTIOXIDANT (scavenges free radicals). (d) VOLUME EXPANSION (improves effective circulating volume → reduces RAAS). INDICATIONS: SBP (1.5 g/kg + 1 g/kg — reduces HRS, Sort 1999), large-volume paracentesis (>5L: 6-8 g albumin per L removed), HRS (1 g/kg × 2 days diagnostic + 20-40 g/day treatment), hepatorenal prevention. A dose-response meta-analysis (Salerno 2015) confirmed higher albumin dose regimens improve HRS reversal.[1][11]
Cardiac dysfunction in HRS (cirrhotic cardiomyopathy). Cirrhosis → cardiac dysfunction (systolic + diastolic) → contributes to HRS: (a) Systolic: reduced contractile reserve (cannot increase cardiac output in response to stress — exercise, sepsis). (b) Diastolic: stiff LV (impaired relaxation — reduced filling). (c) Electrophysiological: prolonged QT (arrhythmia risk). (d) Result: cardiac output insufficient → renal perfusion compromised → HRS. DIAGNOSIS: echocardiography (stress echo for systolic reserve, tissue Doppler for diastolic). MANAGEMENT: treat underlying cirrhosis (transplant resolves cardiomyopathy).[6]
HRS recurrence and relapse. After terlipressin successfully reverses HRS: RELAPSE occurs in ~20-50% (within 2 weeks of stopping). MANAGEMENT: (a) RETREAT with terlipressin + albumin (may work again). (b) If recurrent: consider continuous terlipressin (or noradrenaline infusion). (c) TIPS (if suitable). (d) URGENT liver transplant (HRS will recur until liver transplant). GOAL of medical therapy: BRIDGE to transplant (terlipressin buys time — but doesn't cure — transplant is definitive).[2]
Acute kidney injury in cirrhosis — ADQI classification. Modern approach (ADQI-ISSN 2024): AKI in cirrhosis = creatinine ≥0.3 mg/dL (26.5 μmol/L) in 48h OR ≥50% rise from baseline in 7d. STAGES: Stage 1: 1.5-2.0x baseline. Stage 2: 2.0-3.0x. Stage 3: >3.0x OR RRT OR creatinine >4.0. MANAGEMENT: (a) Stage 1: identify cause, stop nephrotoxins, albumin if volume-depleted. (b) Stage 2: albumin challenge (1 g/kg × 2d — diagnostic). (c) Stage 3: terlipressin if HRS, RRT if refractory, transplant evaluation.[1]
Modern HRS classification — HRS-AKI, HRS-AKD, HRS-CKD (ADQI-iICA 2024). The old type 1/type 2 split is obsolete. NEW classification by TIME COURSE: (a) HRS-AKI: rise of ≥0.3 mg/dL (26.5 μmol/L) in 48h OR ≥50% rise in 7 days (formerly type 1). (b) HRS-AKD (acute kidney disease): AKI criteria not met but creatinine >1.5 mg/dL for <90 days (formerly type 2 — refractory ascites, slow course). (c) HRS-CKD: eGFR <60 for >90 days (chronic, overlaps with CKD of cirrhosis). Key: ALL still require the same ICA diagnostic criteria (no shock, no nephrotoxins, no structural disease, no albumin response).[3]
Confirms criteria and sub-criteria — the albumin challenge details. HRS-AKI requires NO response to albumin challenge of 1 g/kg/day (max 100 g) × 2 consecutive days. Response = decrease of creatinine to <1.5 mg/dL OR ≥50% reduction. Recent consensus ALSO now accepts HRS-AKI diagnosis in patients on diuretics who STILL meet all criteria (old criteria required diuretic cessation first). Serum creatinine UNDERESTIMATES GFR in cirrhosis (low muscle mass, low bilirubin interference) — always interpret cautiously; a cystatin C-based eGFR may be more accurate.[1]
Predictors of response to terlipressin. WHO responds? BETTER response: baseline creatinine <5 mg/dL, serum bilirubin <10 mg/dL, higher MAP, younger age, early initiation (within 7 days of diagnosis). POOR response: baseline creatinine >5 mg/dL (response rate <20%), ACLF grade 3, concomitant sepsis/ATN, hyponatraemia <125. PRACTICE: don't withhold terlipressin based on a single poor predictor, but counsel about reduced response in advanced disease and have a low threshold to switch to noradrenaline or move to RRT if no response by day 4-5.[10]
AKI stage reduction predicts survival (Wong 2020). In CONFIRM and REVERSE pooled analysis, every stage reduction of AKI (per KDIGO) was associated with a ~30% reduction in mortality. HRS reversal (creatinine <1.5) is a SURROGATE for survival benefit even though CONFIRM did not show a statistically significant survival difference at 90 days. IMPLICATION: aim for HRS reversal — it matters even if 90-day survival curves overlap in a single trial.[10]
NGAL and urinary biomarkers — distinguishing HRS from ATN. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is the most studied biomarker. ATN: urinary NGAL HIGH (>220 μg/g creatinine). HRS: urinary NGAL LOW (<100). CUT-OFF around 100-200 μg/g discriminates. CLINICAL USE: helps when FENa and urine Na are confounded (diuretics, AKI), but NOT yet in routine practice in most ICUs — terlipressin trial can be the de-facto discriminator (responds → HRS; no response → ATN).[3]
Terlipressin ischaemic adverse effects — clinical vigilance. CONFIRM trial: serious adverse events leading to discontinuation in 11% vs 2% placebo. ISCHAEMIC EVENTS (overall ~4-12%): MI (rare but reported), mesenteric ischaemia (abdominal pain, lactate rise), digital ischaemia (cold/dusky fingers — reversible on stopping), skin necrosis at infusion site (extravasation). RISK FACTORS: high dose (>8 mg/day bolus), peripheral vascular disease, age >65. PREVENTION: continuous infusion (smoother profile), titrate carefully, stop at first sign of ischaemia.[2]
Respiratory failure — the silent killer of terlipressin therapy. In CONFIRM: respiratory failure 11% terlipressin vs 2% placebo (p=0.01). MECHANISM: not direct lung toxicity — it is FLUID OVERLOAD from concomitant albumin plus improved renal perfusion PLUS splanchnic vasoconstriction redirecting volume centrally. PREVENTION: (a) reduce albumin if patient gains >1 kg/day or develops pulmonary oedema; (b) daily fluid balance, JVP/POCUS/IVC assessment; (c) consider diuretics once renal function improves. This is WHY terlipressin in ICU with close monitoring outperforms ward-based bolus regimens.[2]
Simultaneous liver-kidney (SLK) transplant criteria. HRS is reversible BUT if renal failure is prolonged, the kidney may not recover even after liver transplant. SLK criteria (OPTN 2017, applicable in HRS): dialysis ≥6 weeks WITH evidence of CKD (eGFR <60 for ≥90 days); OR sustained AKI requiring dialysis ≥6 weeks pre-transplant. The 6-week rule is the practical threshold: if HRS patient is on RRT >6 weeks before transplant, evaluate for SLK. RECOVERY: even after SLK, the native kidney may recover in up to 30%, making delayed native-nephrectomy decisions complex.[5]
HRS in acute-on-chronic liver failure (ACLF). ACLF is cirrhosis + acute decompensation + organ failure(s) (CLIF-C ACLF score). HRS-AKI is COMMON in ACLF and often coexists with infection, shock, ATN — pure HRS is rarer than in stable cirrhosis. PRACTICE: in ACLF, often BOTH HRS and ATN coexist (mixed picture). MANAGE: treat infection aggressively, give terlipressin + albumin (lower threshold), expect lower response rates in ACLF grade 3 (~25% response vs ~50% in grade 1). MELD/CLIF scores guide transplant urgency.[5]
Continuous vs intermittent terlipressin. CONTINUOUS INFUSION (2-12 mg/24h): smoother haemodynamics, FEWER ischaemic events, ICU setting, easier titration, slightly higher efficacy in some studies. INTERMITTENT BOLUS (1-2 mg Q4-6h): ward-based, cheaper in nursing time, more peak-related ischaemia, more respiratory failure in CONFIRM (which used bolus). PRACTICE: ICU patient → continuous infusion; ward patient → bolus with close monitoring; SWITCH to continuous if dose escalation needed or ischaemic concerns.[2]
HRS-AKI precipitated by SBP — Sort 1999 landmark trial. Before albumin use, 33% of SBP patients developed HRS. Sort 1999 NEJM: albumin 1.5 g/kg day 1 + 1 g/kg day 3 in high-risk SBP (creatinine >1, bilirubin >4) → HRS 10% vs 33%, 90-day mortality 22% vs 41%. This is the highest-impact intervention in cirrhosis AKI. PRACTICE: ALWAYS give albumin to SBP with renal/bilirubin criteria — no exception. NOT indicated in low-risk SBP (normal creatinine/bilirubin) — no benefit.[7]
Octreotide + midodrine — the weak alternative. Mechanism: octreotide (somatostatin analogue) inhibits splanchnic vasodilators; midodrine (alpha-1 agonist) raises systemic vascular resistance. EVIDENCE: Cavallin 2015 RCT (Hepatology) — terlipressin + albumin SUPERIOR to octreotide + midodrine + albumin (HRS reversal ~50% vs ~15%). Indicated ONLY when terlipressin and noradrenaline BOTH unavailable (rare in ICU). DOSE: octreotide 100-200 mcg SC TDS + midodrine 2.5-7.5 mg PO TDS, titrate to MAP rise of 15 mmHg. CAUTION: not appropriate for ICU patients — go straight to terlipressin/noradrenaline.[8]
Noradrenaline vs terlipressin — head-to-head evidence. Alessandria 2007 (J Hepatol, n=22): noradrenaline (0.1-0.7 mg/h titrated) vs terlipressin — noradrenaline non-inferior for HRS reversal (83% vs 43%, p=0.05) with fewer serious adverse events. Subsequent meta-analyses (Jiang 2023, Ghosh 2013) confirm non-inferiority of noradrenaline. PRACTICE: noradrenaline is the ICU first-line when terlipressin unavailable OR when high ischaemic risk OR when continuous titration is needed. Cost-saving: noradrenaline is dramatically cheaper than terlipressin. LIMITATION: requires central line + ICU bed (not feasible on the ward).[9]
Splanchnic pathophysiology — molecular drivers. The vasodilation cascade: portal hypertension → shear stress + bacterial translocation → upregulation of nitric oxide synthase (eNOS, iNOS) in splanchnic endothelium, increased CO (carbon monoxide from haem oxygenase), endocannabinoids, glucagon, calcitonin gene-related peptide (CGRP). NET EFFECT: massive splanchnic vasodilation, low systemic vascular resistance (SVR), high cardiac output (hyperdynamic circulation). The body senses a 'low effective arterial volume' and mounts the classic compensatory response: RAAS, SNS, non-osmotic ADH — causing intense renal vasoconstriction + sodium/water retention (ascites, dilutional hyponatraemia).[1]
Refractory HRS and RRT as bridge. When terlipressin + albumin FAILS (no response by day 7-14, or progressing ACLF): start RRT as BRIDGE to transplant (NOT destination therapy — HRS without transplant is universally fatal). MODALITY: CRRT (CVVHDF) preferred in haemodynamically unstable cirrhotics; SLED as alternative; intermittent HD only if stable. ANTICOAGULATION: citrate preferred (regional anticoagulation, no systemic effect, less bleeding) — but WATCH calcium (citrate toxicity) and the risk of citrate accumulation in severe liver failure (use heparin instead). TIMING: refer URGENTLY for transplant; HRS-on-RRT >6 weeks → consider SLK.[5]

Red flags

Critical HRS red flags

HRS-AKI: mortality 80% at 2 weeks UNTREATED — rapid diagnosis and treatment essential.[1]
Albumin challenge (1 g/kg × 48h) is DIAGNOSTIC — no improvement → HRS.[1]
Terlipressin + albumin — CONFIRM trial: first FDA-approved (32% reversal).[2]
NSAIDs CONTRAINDICATED in cirrhosis (worsen HRS).[3]
SBP is #1 precipitant — prophylactic albumin (1.5/1 g/kg) reduces HRS.[1]
Liver transplant is DEFINITIVE — HRS is reversible (functional, not structural).[5]
Type 1 HRS median survival ~2 weeks UNTREATED — every hour counts; initiate albumin challenge immediately on admission.[1]
Terlipressin RESPIRATORY FAILURE (11% in CONFIRM) — fluid overload from albumin; reduce albumin if weight gain >1 kg/day or pulmonary oedema.[2]
Terlipressin ISCHAEMIC events (MI, mesenteric, digital — 4-12%) — STOP at first sign; continuous infusion safer than bolus.[2]
ALL NSAIDs and aminoglycosides CONTRAINDICATED in cirrhotic ascites — cause or worsen HRS.[5]
Beta-blockers may HARM in refractory ascites/HRS — STOP if SBP <90, MAP <65, or AKI develops (Mandorfer 2014).[6]
HRS on RRT >6 weeks → evaluate for simultaneous liver-kidney transplant — native kidney may not recover.[5]

Prognosis

CONFIRM trial (Wong 2021, NEJM) — terlipressin for HRS

RCT: 300 patients with HRS type 1. Terlipressin + albumin vs placebo + albumin.

Primary outcome (HRS reversal — 2 consecutive creatinine ≤1.5 mg/dL, ≥2h apart, without RRT, ≥10 days):
- Terlipressin: 32% (vs placebo 17%, p=0.006 — SIGNIFICANT)
Need for RRT at day 90: 28% vs 32% (NS — trend favouring terlipressin)
Survival at day 90: 51% vs 45% (NS — no survival benefit)
Respiratory failure: 11% vs 2% (p=0.01 — MORE with terlipressin — from fluid overload/albumin)
CONCLUSION: Terlipressin improves HRS reversal (32% vs 17%) but does NOT improve survival. Caution: respiratory failure (fluid overload). First FDA-approved HRS therapy. [1]

[1]

REVERSE trial (Boyer 2016, Gastroenterology) — terlipressin for HRS-1

RCT: 178 patients with HRS type 1. Terlipressin + albumin vs placebo + albumin. Terlipressin 1 mg IV Q6h (titrated to 2 mg Q6h from day 4 if no response), albumin 25 g/day.

Primary outcome (HRS reversal — 2 consecutive creatinine ≤1.5 mg/dL ≥2h apart):
- Terlipressin: 19% (vs placebo 13%, p=NS — NOT significant in ITT analysis)
Per-protocol/verified HRS-1 subset: 23% vs 13% (p<0.05)
RRT need: 28% vs 32% (NS)
Survival at day 90: 51% vs 47% (NS)
CONCLUSION: REVERSE was NEUTRAL in the primary analysis — underpowered and confounded by inclusion of non-HRS AKI (~30% misclassified). Pooled with CONFIRM, it supports terlipressin efficacy in confirmed HRS-1. Established the importance of STRICT diagnostic criteria (albumin challenge mandatory) before enrolment.[4]

Cavallin 2015 (Hepatology) — terlipressin vs octreotide/midodrine for HRS

RCT: 78 patients with HRS (type 1 and 2). Terlipressin + albumin vs octreotide + midodrine + albumin.

Terlipressin: 1-2 mg IV Q12h; octreotide: 100-200 mcg SC TDS; midodrine: 2.5-7.5 mg PO TDS; all + albumin 20-40 g/day.
Primary outcome (sustained HRS reversal — creatinine <1.5 mg/dL without RRT):
- Terlipressin: 50% (vs octreotide/midodrine 14%, p=0.009 — SIGNIFICANT)
Recurrence: 25% vs 67% (terlipressin lower)
Survival: NS between groups
CONCLUSION: Terlipressin is SUPERIOR to the octreotide + midodrine combination. Octreotide + midodrine is a last-resort regimen ONLY when vasoconstrictor alternatives are unavailable. This trial solidified terlipressin (and noradrenaline) as the preferred agents.[8]

Sort 1999 (NEJM) — albumin in SBP prevents HRS

RCT: 126 patients with cirrhosis and SBP. IV albumin + antibiotics vs antibiotics alone. Albumin 1.5 g/kg day 1 + 1 g/kg day 3 in patients at risk (creatinine >1 mg/dL or bilirubin >4 mg/dL).

Primary outcomes:
- HRS incidence: 10% (albumin) vs 33% (controls, p=0.007)
- 3-month mortality: 22% vs 41% (p=0.03)
- Renal impairment: 13% vs 38% (p=0.002)
CONCLUSION: IV albumin in high-risk SBP HALVES HRS incidence and improves survival. This is the foundational evidence for the universal recommendation of albumin in SBP with renal/bilirubin criteria — a landmark in hepatology and a cornerstone of HRS PREVENTION.[7]

Alessandria 2007 (J Hepatol) — noradrenaline vs terlipressin

RCT: 22 patients with HRS-1/2. Noradrenaline infusion vs terlipressin bolus + albumin.

Noradrenaline: 0.1-0.7 mg/h titrated to MAP; terlipressin: 1-2 mg Q12h.
Primary outcome (HRS reversal):
- Noradrenaline: 83% (vs terlipressin 43%, p=0.05)
Recurrence: similar
Adverse events: fewer serious ischaemic events with noradrenaline
CONCLUSION: PILOT study (small, unblinded) — noradrenaline appeared NON-INFERIOR (and in this small sample, possibly superior) to terlipressin, with fewer ischaemic events. Subsequent meta-analyses (Ghosh 2013, Jiang 2023, n>500) confirm non-inferiority. PRACTICE: noradrenaline is a legitimate ICU first-line alternative — cheaper, more available, smoother titration, requires central line.[9]

Wong 2020 (NDT) — AKI stage reduction predicts survival in HRS-1

Pooled analysis of CONFIRM + REVERSE (n=466). Tested whether REDUCTION in AKI stage (per KDIGO) predicts survival.

Primary finding: For every AKI stage reduction, mortality fell ~30% (HR 0.70, p<0.01).
HRS reversal (creatinine <1.5): 90-day survival 70% (reversal) vs 38% (no reversal, p<0.001).
CONCLUSION: HRS reversal IS a meaningful surrogate for survival — the lack of statistically significant survival benefit in CONFIRM alone was a power issue, not a lack of biological benefit. REINFORCES the goal of treatment: achieve HRS reversal (terlipressin + albumin, escalate to max dose, switch to noradrenaline if failing).[10]

Exam pitfalls

Trap: 'HRS kidney is structurally damaged' → FALSE. The kidney is HISTOLOGICALLY NORMAL in HRS. It is a FUNCTIONAL/vasomotor syndrome — proof: HRS kidney transplanted into a healthy recipient functions normally; HRS resolves with liver transplant.
Trap: 'Diuretics must be stopped before HRS diagnosis' → OLD criteria. The ADQI-iICA 2024 consensus ALLOWS HRS diagnosis while on diuretics if all other criteria are met.
Trap: 'FENa <1% rules out ATN' → FALSE. FENa is unreliable in cirrhosis (diuretics, low sodium intake, low GFR). Urinary NGAL and the response to terlipressin are better discriminators.
Trap: 'HRS and ATN are mutually exclusive' → FALSE. In ACLF, sepsis, and ICU patients, MIXED HRS + ATN is common — treat both (terlipressin + albumin AND treat the precipitating cause).
Trap: 'Terlipressin improves survival in HRS' → NUANCED. CONFIRM did NOT show a statistically significant 90-day survival benefit, BUT pooled data (Wong 2020) show reversal reduces mortality ~30% per stage. The trial endpoint (reversal) IS clinically meaningful.
Trap: 'Albumin challenge for HRS = 1.5 g/kg' → FALSE. The HRS DIAGNOSTIC albumin challenge is 1 g/kg/day (max 100 g) × 2 days. The SBP PROPHYLAXIS albumin regimen is 1.5 g/kg day 1 + 1 g/kg day 3 — DIFFERENT doses for DIFFERENT purposes.
Trap: 'Type 2 HRS = stable, treat as outpatient' → PARTLY TRUE. Type 2 (now HRS-AKD) is slower, BUT mortality at 6 months is still ~70% untreated — refer for transplant early; TIPS may help selected patients.
Trap: 'TIPS is contraindicated in HRS because of encephalopathy' → OVERSIMPLIFIED. TIPS is CONTRAINDICATED in severe encephalopathy (and MELD >18, severe cardiopulmonary disease), but it is a valid option in selected HRS-AKD patients with refractory ascites.
Trap: 'HRS recurs after transplant so transplant doesn't help' → FALSE. HRS resolves in 60-80% after liver transplant (functional kidney failure recovers). Recurrence after terlipressin is common (20-50%) — that's why transplant (not just terlipressin) is the definitive cure. [1]

References

[1]Angeli P, Garcia-Tsao G, Nadim MK, et al. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document J Hepatol, 2019.PMID 31302175
[2]Wong F, Pappas SC, Curry MP, et al. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome N Engl J Med, 2021.PMID 33657294
[3]Nadim MK, Kellum JA, Forni L, et al. Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting J Hepatol, 2024.PMID 38527522
[4]Boyer TD, Sanyal AJ, Wong F, et al. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1 Gastroenterology, 2016.PMID 26896734
[5]Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases Hepatology, 2021.PMID 33942342
[6]Bucsics T, Schwabl P, Mandorfer M, et al. The trigger matters - outcome of hepatorenal syndrome vs. specifically triggered acute kidney injury in cirrhotic patients with ascites Liver Int, 2016.PMID 27169985
[7]Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis N Engl J Med, 1999.PMID 10432325
[8]Cavallin M, Kamath PS, Merli M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial Hepatology, 2015.PMID 25644760
[9]Alessandria C, Ottobrelli A, Debernardi-Venon W, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study J Hepatol, 2007.PMID 17560680
[10]Wong F, Boyer TD, Sanyal AJ, et al. Reduction in acute kidney injury stage predicts survival in patients with type-1 hepatorenal syndrome Nephrol Dial Transplant, 2020.PMID 30887050
[11]Salerno F, Navickis RJ, Wilkes MM. Albumin treatment regimen for type 1 hepatorenal syndrome: a dose-response meta-analysis BMC Gastroenterol, 2015.PMID 26606982

Your progress

Exam practice

SAQ — HRS-AKI in decompensated cirrhosis: terlipressin and albumin

SAQ — Differentiating HRS from acute tubular necrosis (ATN) in a cirrhotic patient

Clinical pearls

Red flags

Prognosis

CONFIRM trial (Wong 2021, NEJM) — terlipressin for HRS

REVERSE trial (Boyer 2016, Gastroenterology) — terlipressin for HRS-1

Cavallin 2015 (Hepatology) — terlipressin vs octreotide/midodrine for HRS

Sort 1999 (NEJM) — albumin in SBP prevents HRS

Alessandria 2007 (J Hepatol) — noradrenaline vs terlipressin

Wong 2020 (NDT) — AKI stage reduction predicts survival in HRS-1

Exam pitfalls

References

Hepatorenal syndrome: diagnosis, management, and terlipressin

Your progress

Exam practice

SAQ — HRS-AKI in decompensated cirrhosis: terlipressin and albumin

SAQ — Differentiating HRS from acute tubular necrosis (ATN) in a cirrhotic patient

Clinical pearls

Red flags

Prognosis

CONFIRM trial (Wong 2021, NEJM) — terlipressin for HRS

REVERSE trial (Boyer 2016, Gastroenterology) — terlipressin for HRS-1

Cavallin 2015 (Hepatology) — terlipressin vs octreotide/midodrine for HRS

Sort 1999 (NEJM) — albumin in SBP prevents HRS

Alessandria 2007 (J Hepatol) — noradrenaline vs terlipressin

Wong 2020 (NDT) — AKI stage reduction predicts survival in HRS-1

Exam pitfalls

References